Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (5)
- Doctoral Thesis (1)
Keywords
- T cells (2)
- Alpha therapy (1)
- Autoimmune diseases (1)
- B cells (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- CNS cancer (1)
- Cancer treatment (1)
- Expression (1)
- Factor receptor (1)
- Gemcitabin (1)
- Graft-versus-leukemia (1)
- Lymphomas (1)
- Medulloblastom (1)
- Neuroblastom (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Spleen (1)
- Suppression (1)
- Tumor-necrosis-factor (1)
- Xenograft (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- brain tumor (1)
- cancer (1)
- cancer stem cells (1)
- cancer treatment (1)
- cell staining (1)
- children (1)
- cytokines (1)
- group 3 (1)
- immune cells (1)
- metastasis (1)
- orthotopic xenograft (1)
- paediatric cancer (1)
- regulatory T cells (1)
Institute
- Medizinische Klinik und Poliklinik II (5)
- Kinderklinik und Poliklinik (3)
- Pathologisches Institut (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Neurochirurgische Klinik und Poliklinik (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Graduate School of Life Sciences (1)
- Institut für Virologie und Immunbiologie (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (1)
Sonstige beteiligte Institutionen
Medulloblastoma is the most common high-grade brain tumor in childhood. Medulloblastomas with c-myc amplification, classified as group 3, are the most aggressive among the four disease subtypes resulting in a 5-year overall survival of just above 50%. Despite current intensive therapy regimens, patients suffering from group 3 medulloblastoma urgently require new therapeutic options. Using a recently established c-myc amplified human medulloblastoma cell line, we performed an in-vitro-drug screen with single and combinatorial drugs that are either already clinically approved or agents in the advanced stage of clinical development. Candidate drugs were identified in vitro and then evaluated in vivo. Tumor growth was closely monitored by BLI. Vessel development was assessed by 3D light-sheet-fluorescence-microscopy. We identified the combination of gemcitabine and axitinib to be highly cytotoxic, requiring only low picomolar concentrations when used in combination. In the orthotopic model, gemcitabine and axitinib showed efficacy in terms of tumor control and survival. In both models, gemcitabine and axitinib were better tolerated than the standard regimen comprising of cisplatin and etoposide phosphate. 3D light-sheet-fluorescence-microscopy of intact tumors revealed thinning and rarefication of tumor vessels, providing one explanation for reduced tumor growth. Thus, the combination of the two drugs gemcitabine and axitinib has favorable effects on preventing tumor progression in an orthotopic group 3 medulloblastoma xenograft model while exhibiting a favorable toxicity profile. The combination merits further exploration as a new approach to treat high-risk group 3 medulloblastoma.